A forum for researchers, students and applicants in the field of cyclodextrin technology
The team of Gerhard Wenz (Saarland University, Germany) has published a novel polyrotaxane: hydroxypropyl-β-cyclodextrin(HPBCD):poly(decamethylenephosphate) which has several advantages over HPBCD
Sepsis is an often deadly complication of infection in which systemic inflammation damages the vasculature, leading to tissue hypoperfusion and
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
CTD Holdings, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need,
Variant Pharmaceuticals, Inc received US Food and Drug Administration (FDA) has approval for the development of VAR 200 (2-hydroxypropyl-β-cyclodextrin, or
The CDNews blog was created in July and after a short period of trial it started in September. During this
Nitric oxide (NO) is a signaling molecule produced by almost all types of organisms ranging from bacteria to plants and
In a recently published Nature report it was investigated how tumor cells respond to different forms of sugar [1]. It
Mallinckrodt Pharmaceuticals recently revealed findings of their completed registration trial for VTS-270 (Hydroxypropyl Betadex- HPBCD), a development product to treat
A recently published patent application of Cell and Molecular Tissue Engineering LLC (WO2017180708) discloses a method of lowering the concentrations of
